Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10

Finnish Institute for Health and Welfare186 enrolled

Overview

The aim of the study are to assess the persistence of immunity against vaccine serotypes (VSTs) and vaccine-related serotypes in PCV10 vaccinated children in Finland.

The primary objective is to evaluate the long-term persistence of humoral immunity to vaccine-related pneumococcal serotypes after vaccination with PCV10.

Study Type

OBSERVATIONAL

Enrollment

186

Conditions

Pneumococcal Infections

Interventions

10-valent pneumococcal conjugate vaccine, PCV10BIOLOGICAL

10-valent pneumococcal conjugate vaccine, PCV10

Eligibility

Sex: ALLMin age: 13 MonthsMax age: 3 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Completed PCV10 vaccination with 3 or 4 doses (2+1 or 3+1 schedule) before blood sampling at age of 13 months * Age at sample collection 13 months, 2 years or 3 years * PCV10 vaccination received 2-6 weeks before sample collection at the age of 1 year * Informed consent obtained covering the planned analyses Exclusion Criteria: * PCV13 or PPV23 dose received * Informed consent withdrawn

Locations (1)

Finnish Institute for Health and Welfare

Helsinki, Finland

Outcomes

Primary Outcomes

Persistence of Humoral Immunity Following PCV10 Vaccination

Persistence of humoral immunity to vaccine- and vaccine-related pneumococcal serotypes after vaccination with PCV10. The serotype 19A specific geometric mean IgG antibody concentrations are reported as micrograms per ml with 95% confidence intervals.

Time frame: Two years following last PCV10 vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.